betamethasone (SURF-201) / Harrow Health - LARVOL DELTA

0.2% Betamethasone Sodium Phosphate: A Multicenter, Randomized, Double-Masked Study to Compare Its Ocular Safety, Tolerability, and Efficacy to Vehicle in Cataract Surgery Subjects. (PubMed, Clin Ophthalmol) - "A slightly higher incidence of adverse events occurred in subjects in the SURF-201 treatment group (n=27/40 [67.5%]) compared to the vehicle treatment group (n=23/43 [53.5%]). SURF-201 is an effective topical, preservative-free corticosteroid when dosed BID for the treatment of postoperative inflammation and prevention of pain in a post-cataract population."

Clinical • Surgery • Cataract • Inflammation • Ocular Inflammation • Ophthalmology • Pain

A Research Study to See How Well an Eye Drop, SURF-201 (0.2% Ophthalmic Corticosteroid Solution), Works, What Side Effects There Are, and to Compare it With Vehicle (Placebo) in Subjects That Undergo Cataract Surgery. (clinicaltrials.gov) - P2; N=91; Completed; Sponsor: Surface Pharmaceuticals, Inc.; Recruiting ➔ Completed; Trial completion date: Jul 2020 ➔ Nov 2020; Trial primary completion date: Jul 2020 ➔ Nov 2020

Adverse events • Clinical • Trial completion • Trial completion date • Trial primary completion date • Cataract • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pain